JEWISH GENERAL HOSPITAL

Telo Genomics Launches Blood-Based MRD Study for Multiple Myeloma with University of Athens

- Telo Genomics has initiated a retrospective multiple myeloma minimal residual disease clinical trial in collaboration with the University of Athens as part of its expanding multi-center validation program. - The study will evaluate TeloView MRD's prognostic performance in predicting relapse risk compared to Next-Generation Flow, with access to well-characterized blood samples and three years of patient follow-up data. - TeloView MRD is designed to detect disease at high sensitivity down to 1 in 10^7 cells and analyzes 3D genomic architecture of individual MRD cells for enhanced prognostic insights. - The collaboration strengthens Telo's mission to redefine MRD-guided clinical practice following FDA's unanimous acceptance of MRD as a clinical endpoint for accelerated multiple myeloma therapy approvals.